Funder
Deutsche Forschungsgemeinschaft
Reference10 articles.
1. FDA Investigating Serious Risk of T-Cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies;Research,2023
2. Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies;Skeate;Mol. Ther.,2024
3. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors;Bexte;Mol. Ther.,2024
4. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors;Monjezi;Leukemia,2017
5. Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas;Srour;Blood,2020